Matthew Fuller

Energizer
DISC Type : I

Vice President - Head of Gene Therapy Research at Ultragenyx

Cambridge, Massachusetts, United States

Overview

Matthew is a PhD-level molecular biologist and virologist with over 17 years of experience. As the Head of Gene Therapy Research at Ultragenyx, he leads a cross-functional team of 40 researchers focused on optimizing gene therapy platforms for liver, CNS, and muscle programs.

Outside of his primary role, Matthew is deeply committed to advancing cures for rare diseases. He volunteers extensively as a member of the scientific advisory boards for several patient advocacy groups, including the Coalition to Cure CHD2, IDefine, and the Myhre Syndrome Foundation.

He serves as the Chief Scientific Advisor for the Cohen Syndrome Association, highlighting his dedication to specific rare disease communities.

Personality Overview

Big Picture Person

Believer

Informal

They are friendly, approachable and love to make new connections.  They are always positive and upbeat, so take their promises with a pinch of salt. They are really good at seeing what the long-term impacts of their decisions could be.

Topics They Care About

Rare Disease Advocacy
Volunteers on the scientific advisory boards for multiple foundations dedicated to specific rare conditions like Kleefstra, Myhre, and Cohen syndromes.
Gene Therapy Platforms
Leads a large research team at Ultragenyx focused on the continual optimization and investment in AAV-based gene therapy platforms and programs.
AAV Biology
Serves as a volunteer member of the FNIH Bespoke Gene Therapy Consortium's AAV Biology subteam, contributing to foundational vector research.

Media Appearances

On Rare Disease Day, Ultragenyx’s Head of Gene Therapy Research Matthew Fuller discusses the future of rare disease therapies. Featured in BiotechTV – Apple Podcasts

See Now

WIR 2024 T3: Is Our Community Ready for Gene Therapy? – Featuring Matthew Fuller, Vice President & Head of Gene Therapy Research, Ultragenyx. Featured in YouTube

See Now

Winter 2023‑2024 Ultragenyx Patient Advocacy Newsletter – includes interview with Matthew Fuller, VP – Head of Gene Therapy Research. Featured in Ultragenyx Patient Advocacy (PDF)

See Now

Work History

8-2024
Vice President - Head of Gene Therapy Research at Ultragenyx
3-2023 - 8-2024
Executive Director - Gene Therapy Research at Ultragenyx
2-2022 - 3-2023
Senior Director - Vector Platform Research at Ultragenyx
11-2019 - 2-2022
Director - Vector Platform Research at Ultragenyx
4-2019 - 11-2019
Associate Director - Head of Vector Engineering at Ultragenyx

Education

2011 - 2016
Doctor of Philosophy (PhD) from University of Missouri-Columbia
2004 - 2006
MSPH from Tulane University Celia Scott Weatherhead School of Public Health and Tropical Medicine

More Information

Social Presence :

Prographics :

Exp : 14 Location : Cambridge, Massachusetts, United States Job Level : Senior Designation : Vice President - Head of Gene Therapy Research at Ultragenyx
URL has been copied!

Insights For Selling To Matthew

During A Call Or A Meeting

DO's

  • Talk about their team and how your product will help them do things better and easier
  • Speak enthusiastically with energy, maintain a clear and confident tone
  • Share some stories about how you you have helped people in similar positions succeed

DONT's

  • Avoid overloading them with too much detail
  • Don’t assume a yes just because they have not said no
  • Avoid ifs and buts, don’t talk too much about the risks etc.

When Cold Calling

When Writing An Email

While Negotiating & Closing

    The secret to closing fast with Matthew is

  • Relationship and rapport can play an important role, sometimes more than the other factors.
  • Will you ever get a clear answer from Matthew

  • They will probably never say no directly, you have to make that decision yourself.

Insights For Deal Planning

    How fast (or slow) will Matthew move?

  • They are not the quickest decision makers, their friendly attitude could be misleading.
  • Can Matthew take some risk or not?

  • They can accept limited risks, ones that they think will not impact them personally.

You And Matthew

Personality Compatibility


Other Ultragenyx Employees

Explore more public profiles from related professionals at the same organization.

More Profiles

Discover additional public profiles from our index.

Search more profiles

Looking for someone else? Search here for anyone.

Or visit Humantic AI to know more.